nodes	percent_of_prediction	percent_of_DWPC	metapath
Icosapent—PTGS2—Lenalidomide—hematologic cancer	0.105	0.209	CbGbCtD
Icosapent—PTGS2—Thalidomide—hematologic cancer	0.0558	0.111	CbGbCtD
Icosapent—PTGS1—Bortezomib—hematologic cancer	0.0541	0.108	CbGbCtD
Icosapent—PTGS1—Thalidomide—hematologic cancer	0.0471	0.0941	CbGbCtD
Icosapent—PTGS1—Ifosfamide—hematologic cancer	0.0415	0.0828	CbGbCtD
Icosapent—PTGS1—Imatinib—hematologic cancer	0.0397	0.0791	CbGbCtD
Icosapent—PTGS2—Triamcinolone—hematologic cancer	0.0387	0.0772	CbGbCtD
Icosapent—PTGS2—Betamethasone—hematologic cancer	0.0332	0.0662	CbGbCtD
Icosapent—PTGS2—Cisplatin—hematologic cancer	0.0239	0.0477	CbGbCtD
Icosapent—PTGS2—Etoposide—hematologic cancer	0.0235	0.0469	CbGbCtD
Icosapent—PTGS1—Etoposide—hematologic cancer	0.0198	0.0396	CbGbCtD
Icosapent—PTGS2—Dexamethasone—hematologic cancer	0.0193	0.0385	CbGbCtD
Icosapent—PTGS2—ovarian follicle—hematologic cancer	0.0084	0.086	CbGeAlD
Icosapent—SLC8A1—hematopoietic system—hematologic cancer	0.00728	0.0746	CbGeAlD
Icosapent—ACSL3—gonad—hematologic cancer	0.00668	0.0684	CbGeAlD
Icosapent—ACSL3—lung—hematologic cancer	0.0051	0.0523	CbGeAlD
Icosapent—ACSL3—testis—hematologic cancer	0.00481	0.0493	CbGeAlD
Icosapent—ACSL4—hematopoietic system—hematologic cancer	0.00441	0.0452	CbGeAlD
Icosapent—PPARD—hematopoietic system—hematologic cancer	0.00423	0.0434	CbGeAlD
Icosapent—TRPV1—gonad—hematologic cancer	0.00369	0.0378	CbGeAlD
Icosapent—ACSL4—gonad—hematologic cancer	0.00335	0.0344	CbGeAlD
Icosapent—FADS1—blood—hematologic cancer	0.00322	0.033	CbGeAlD
Icosapent—FADS1—bone marrow—hematologic cancer	0.00311	0.0319	CbGeAlD
Icosapent—ACSL4—blood—hematologic cancer	0.00292	0.0299	CbGeAlD
Icosapent—ACSL4—bone marrow—hematologic cancer	0.00283	0.029	CbGeAlD
Icosapent—FADS1—lung—hematologic cancer	0.00282	0.0289	CbGeAlD
Icosapent—FADS1—testis—hematologic cancer	0.00266	0.0273	CbGeAlD
Icosapent—TRPV1—testis—hematologic cancer	0.00266	0.0273	CbGeAlD
Icosapent—ACSL4—lung—hematologic cancer	0.00256	0.0262	CbGeAlD
Icosapent—PPARD—lung—hematologic cancer	0.00246	0.0252	CbGeAlD
Icosapent—ACSL4—testis—hematologic cancer	0.00242	0.0248	CbGeAlD
Icosapent—PPARD—testis—hematologic cancer	0.00232	0.0238	CbGeAlD
Icosapent—PPARG—hematopoietic system—hematologic cancer	0.00198	0.0203	CbGeAlD
Icosapent—FADS1—lymph node—hematologic cancer	0.00193	0.0198	CbGeAlD
Icosapent—ACSL4—lymph node—hematologic cancer	0.00175	0.0179	CbGeAlD
Icosapent—PPARD—lymph node—hematologic cancer	0.00168	0.0172	CbGeAlD
Icosapent—PPARG—Ponatinib—Nilotinib—hematologic cancer	0.00134	0.24	CbGdCrCtD
Icosapent—PPARG—blood—hematologic cancer	0.00131	0.0135	CbGeAlD
Icosapent—PPARG—bone marrow—hematologic cancer	0.00127	0.013	CbGeAlD
Icosapent—PPARG—lung—hematologic cancer	0.00115	0.0118	CbGeAlD
Icosapent—PPARG—testis—hematologic cancer	0.00109	0.0111	CbGeAlD
Icosapent—PTGS1—hematopoietic system—hematologic cancer	0.00106	0.0109	CbGeAlD
Icosapent—PPARG—Ponatinib—Imatinib—hematologic cancer	0.00102	0.182	CbGdCrCtD
Icosapent—PTGS2—hematopoietic system—hematologic cancer	0.00101	0.0104	CbGeAlD
Icosapent—PPARG—Topotecan—Irinotecan—hematologic cancer	0.000964	0.172	CbGdCrCtD
Icosapent—PPARG—Etoposide—Teniposide—hematologic cancer	0.000958	0.171	CbGdCrCtD
Icosapent—PPARG—lymph node—hematologic cancer	0.000788	0.00807	CbGeAlD
Icosapent—PTGS1—blood—hematologic cancer	0.000703	0.0072	CbGeAlD
Icosapent—PTGS2—blood—hematologic cancer	0.000671	0.00688	CbGeAlD
Icosapent—PTGS2—bone marrow—hematologic cancer	0.00065	0.00666	CbGeAlD
Icosapent—PTGS1—lung—hematologic cancer	0.000616	0.00631	CbGeAlD
Icosapent—PTGS2—lung—hematologic cancer	0.000589	0.00603	CbGeAlD
Icosapent—PTGS1—testis—hematologic cancer	0.000581	0.00596	CbGeAlD
Icosapent—PPARG—Teniposide—Etoposide—hematologic cancer	0.000434	0.0777	CbGdCrCtD
Icosapent—PTGS1—lymph node—hematologic cancer	0.000421	0.00432	CbGeAlD
Icosapent—PTGS2—lymph node—hematologic cancer	0.000403	0.00413	CbGeAlD
Icosapent—Anaphylactic shock—Bortezomib—hematologic cancer	0.000365	0.002	CcSEcCtD
Icosapent—Rash—Idarubicin—hematologic cancer	0.000364	0.00199	CcSEcCtD
Icosapent—Dermatitis—Idarubicin—hematologic cancer	0.000364	0.00199	CcSEcCtD
Icosapent—Anaphylactic shock—Bleomycin—hematologic cancer	0.000362	0.00198	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Lenalidomide—hematologic cancer	0.000361	0.00198	CcSEcCtD
Icosapent—Dyspepsia—Melphalan—hematologic cancer	0.000359	0.00197	CcSEcCtD
Icosapent—Pruritus—Procarbazine—hematologic cancer	0.000358	0.00196	CcSEcCtD
Icosapent—Vomiting—Teniposide—hematologic cancer	0.000357	0.00196	CcSEcCtD
Icosapent—Anaphylactic shock—Vinorelbine—hematologic cancer	0.000357	0.00195	CcSEcCtD
Icosapent—Arthralgia—Thiotepa—hematologic cancer	0.000355	0.00194	CcSEcCtD
Icosapent—Rash—Teniposide—hematologic cancer	0.000355	0.00194	CcSEcCtD
Icosapent—Dermatitis—Teniposide—hematologic cancer	0.000354	0.00194	CcSEcCtD
Icosapent—Dysgeusia—Mitoxantrone—hematologic cancer	0.000353	0.00193	CcSEcCtD
Icosapent—Gastrointestinal disorder—Melphalan—hematologic cancer	0.000352	0.00193	CcSEcCtD
Icosapent—Pruritus—Dasatinib—hematologic cancer	0.000351	0.00192	CcSEcCtD
Icosapent—Pruritus—Bexarotene—hematologic cancer	0.000351	0.00192	CcSEcCtD
Icosapent—Pruritus—Fludarabine—hematologic cancer	0.00035	0.00191	CcSEcCtD
Icosapent—Eructation—Doxorubicin—hematologic cancer	0.000349	0.00191	CcSEcCtD
Icosapent—Dyspepsia—Lenalidomide—hematologic cancer	0.000349	0.00191	CcSEcCtD
Icosapent—Dyspepsia—Hydroxyurea—hematologic cancer	0.000344	0.00188	CcSEcCtD
Icosapent—Arthralgia—Thalidomide—hematologic cancer	0.000344	0.00188	CcSEcCtD
Icosapent—Gastrointestinal disorder—Lenalidomide—hematologic cancer	0.000343	0.00187	CcSEcCtD
Icosapent—Constipation—Lenalidomide—hematologic cancer	0.000339	0.00186	CcSEcCtD
Icosapent—Gastrointestinal disorder—Hydroxyurea—hematologic cancer	0.000338	0.00185	CcSEcCtD
Icosapent—Constipation—Hydroxyurea—hematologic cancer	0.000335	0.00183	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Bortezomib—hematologic cancer	0.000333	0.00182	CcSEcCtD
Icosapent—Vomiting—Busulfan—hematologic cancer	0.000331	0.00181	CcSEcCtD
Icosapent—Pruritus—Chlorambucil—hematologic cancer	0.000331	0.00181	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Bleomycin—hematologic cancer	0.00033	0.00181	CcSEcCtD
Icosapent—Rash—Busulfan—hematologic cancer	0.000329	0.0018	CcSEcCtD
Icosapent—Dermatitis—Busulfan—hematologic cancer	0.000328	0.0018	CcSEcCtD
Icosapent—Malnutrition—Cisplatin—hematologic cancer	0.000327	0.00179	CcSEcCtD
Icosapent—Arthralgia—Alitretinoin—hematologic cancer	0.000327	0.00179	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Vinorelbine—hematologic cancer	0.000325	0.00178	CcSEcCtD
Icosapent—Pruritus—Nilotinib—hematologic cancer	0.000324	0.00177	CcSEcCtD
Icosapent—Arthralgia—Ifosfamide—hematologic cancer	0.000323	0.00177	CcSEcCtD
Icosapent—Pruritus—Imatinib—hematologic cancer	0.000322	0.00176	CcSEcCtD
Icosapent—Vomiting—Procarbazine—hematologic cancer	0.000321	0.00176	CcSEcCtD
Icosapent—Dyspepsia—Bortezomib—hematologic cancer	0.000321	0.00176	CcSEcCtD
Icosapent—Rash—Procarbazine—hematologic cancer	0.000319	0.00174	CcSEcCtD
Icosapent—Dermatitis—Procarbazine—hematologic cancer	0.000318	0.00174	CcSEcCtD
Icosapent—Pruritus—Cladribine—hematologic cancer	0.000316	0.00173	CcSEcCtD
Icosapent—Gastrointestinal disorder—Bortezomib—hematologic cancer	0.000315	0.00173	CcSEcCtD
Icosapent—Vomiting—Bexarotene—hematologic cancer	0.000315	0.00172	CcSEcCtD
Icosapent—Vomiting—Dasatinib—hematologic cancer	0.000315	0.00172	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Prednisone—hematologic cancer	0.000315	0.00172	CcSEcCtD
Icosapent—Vomiting—Fludarabine—hematologic cancer	0.000314	0.00172	CcSEcCtD
Icosapent—Anaphylactic shock—Alitretinoin—hematologic cancer	0.000313	0.00171	CcSEcCtD
Icosapent—Rash—Dasatinib—hematologic cancer	0.000312	0.00171	CcSEcCtD
Icosapent—Rash—Bexarotene—hematologic cancer	0.000312	0.00171	CcSEcCtD
Icosapent—Constipation—Bortezomib—hematologic cancer	0.000312	0.00171	CcSEcCtD
Icosapent—Dermatitis—Bexarotene—hematologic cancer	0.000312	0.00171	CcSEcCtD
Icosapent—Dermatitis—Dasatinib—hematologic cancer	0.000312	0.00171	CcSEcCtD
Icosapent—Rash—Fludarabine—hematologic cancer	0.000312	0.00171	CcSEcCtD
Icosapent—Dermatitis—Fludarabine—hematologic cancer	0.000311	0.0017	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Thiotepa—hematologic cancer	0.00031	0.0017	CcSEcCtD
Icosapent—Anaphylactic shock—Ifosfamide—hematologic cancer	0.00031	0.00169	CcSEcCtD
Icosapent—Gastrointestinal disorder—Vinorelbine—hematologic cancer	0.000308	0.00168	CcSEcCtD
Icosapent—Arthralgia—Mitoxantrone—hematologic cancer	0.000307	0.00168	CcSEcCtD
Icosapent—Constipation—Vinorelbine—hematologic cancer	0.000305	0.00167	CcSEcCtD
Icosapent—Anaphylactic shock—Vincristine—hematologic cancer	0.000302	0.00165	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Thalidomide—hematologic cancer	0.0003	0.00164	CcSEcCtD
Icosapent—Dyspepsia—Thiotepa—hematologic cancer	0.0003	0.00164	CcSEcCtD
Icosapent—Arthralgia—Gemcitabine—hematologic cancer	0.000299	0.00164	CcSEcCtD
Icosapent—Vomiting—Chlorambucil—hematologic cancer	0.000298	0.00163	CcSEcCtD
Icosapent—Anaphylactic shock—Irinotecan—hematologic cancer	0.000294	0.00161	CcSEcCtD
Icosapent—Anaphylactic shock—Mitoxantrone—hematologic cancer	0.000294	0.00161	CcSEcCtD
Icosapent—Gastrointestinal disorder—Thiotepa—hematologic cancer	0.000294	0.00161	CcSEcCtD
Icosapent—Dysgeusia—Etoposide—hematologic cancer	0.000293	0.00161	CcSEcCtD
Icosapent—Constipation—Thiotepa—hematologic cancer	0.000291	0.00159	CcSEcCtD
Icosapent—Vomiting—Nilotinib—hematologic cancer	0.000291	0.00159	CcSEcCtD
Icosapent—Dyspepsia—Thalidomide—hematologic cancer	0.00029	0.00159	CcSEcCtD
Icosapent—Vomiting—Imatinib—hematologic cancer	0.000289	0.00158	CcSEcCtD
Icosapent—Pruritus—Melphalan—hematologic cancer	0.000289	0.00158	CcSEcCtD
Icosapent—Rash—Nilotinib—hematologic cancer	0.000289	0.00158	CcSEcCtD
Icosapent—Dermatitis—Nilotinib—hematologic cancer	0.000288	0.00158	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Carmustine—hematologic cancer	0.000288	0.00158	CcSEcCtD
Icosapent—Rash—Imatinib—hematologic cancer	0.000287	0.00157	CcSEcCtD
Icosapent—Dermatitis—Imatinib—hematologic cancer	0.000287	0.00157	CcSEcCtD
Icosapent—Anaphylactic shock—Gemcitabine—hematologic cancer	0.000286	0.00157	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Alitretinoin—hematologic cancer	0.000285	0.00156	CcSEcCtD
Icosapent—Vomiting—Cladribine—hematologic cancer	0.000284	0.00156	CcSEcCtD
Icosapent—Gastrointestinal disorder—Thalidomide—hematologic cancer	0.000284	0.00156	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Ifosfamide—hematologic cancer	0.000282	0.00154	CcSEcCtD
Icosapent—Rash—Cladribine—hematologic cancer	0.000282	0.00154	CcSEcCtD
Icosapent—Dermatitis—Cladribine—hematologic cancer	0.000282	0.00154	CcSEcCtD
Icosapent—Constipation—Thalidomide—hematologic cancer	0.000282	0.00154	CcSEcCtD
Icosapent—Pruritus—Lenalidomide—hematologic cancer	0.000281	0.00154	CcSEcCtD
Icosapent—Dyspepsia—Alitretinoin—hematologic cancer	0.000276	0.00151	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Vincristine—hematologic cancer	0.000275	0.00151	CcSEcCtD
Icosapent—Gastrointestinal disorder—Carmustine—hematologic cancer	0.000273	0.00149	CcSEcCtD
Icosapent—Vomiting—Vinblastine—hematologic cancer	0.000273	0.00149	CcSEcCtD
Icosapent—Gastrointestinal disorder—Alitretinoin—hematologic cancer	0.00027	0.00148	CcSEcCtD
Icosapent—Constipation—Carmustine—hematologic cancer	0.00027	0.00148	CcSEcCtD
Icosapent—Constipation—Alitretinoin—hematologic cancer	0.000268	0.00147	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Mitoxantrone—hematologic cancer	0.000268	0.00147	CcSEcCtD
Icosapent—Gastrointestinal disorder—Ifosfamide—hematologic cancer	0.000267	0.00146	CcSEcCtD
Icosapent—Anaphylactic shock—Cisplatin—hematologic cancer	0.000267	0.00146	CcSEcCtD
Icosapent—Dysgeusia—Triamcinolone—hematologic cancer	0.000266	0.00146	CcSEcCtD
Icosapent—Constipation—Ifosfamide—hematologic cancer	0.000265	0.00145	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Gemcitabine—hematologic cancer	0.000261	0.00143	CcSEcCtD
Icosapent—Gastrointestinal disorder—Vincristine—hematologic cancer	0.000261	0.00143	CcSEcCtD
Icosapent—Vomiting—Melphalan—hematologic cancer	0.000259	0.00142	CcSEcCtD
Icosapent—Dyspepsia—Irinotecan—hematologic cancer	0.000259	0.00142	CcSEcCtD
Icosapent—Dyspepsia—Mitoxantrone—hematologic cancer	0.000259	0.00142	CcSEcCtD
Icosapent—Pruritus—Bortezomib—hematologic cancer	0.000258	0.00141	CcSEcCtD
Icosapent—Constipation—Vincristine—hematologic cancer	0.000258	0.00141	CcSEcCtD
Icosapent—Rash—Melphalan—hematologic cancer	0.000257	0.00141	CcSEcCtD
Icosapent—Dermatitis—Melphalan—hematologic cancer	0.000257	0.00141	CcSEcCtD
Icosapent—Pruritus—Bleomycin—hematologic cancer	0.000256	0.0014	CcSEcCtD
Icosapent—Gastrointestinal disorder—Irinotecan—hematologic cancer	0.000254	0.00139	CcSEcCtD
Icosapent—Vomiting—Lenalidomide—hematologic cancer	0.000252	0.00138	CcSEcCtD
Icosapent—Pruritus—Vinorelbine—hematologic cancer	0.000252	0.00138	CcSEcCtD
Icosapent—Constipation—Mitoxantrone—hematologic cancer	0.000251	0.00138	CcSEcCtD
Icosapent—Constipation—Irinotecan—hematologic cancer	0.000251	0.00138	CcSEcCtD
Icosapent—Aspartate aminotransferase increased—Epirubicin—hematologic cancer	0.000251	0.00137	CcSEcCtD
Icosapent—Rash—Lenalidomide—hematologic cancer	0.00025	0.00137	CcSEcCtD
Icosapent—Dermatitis—Lenalidomide—hematologic cancer	0.00025	0.00137	CcSEcCtD
Icosapent—Vomiting—Hydroxyurea—hematologic cancer	0.000249	0.00136	CcSEcCtD
Icosapent—Gastrointestinal disorder—Gemcitabine—hematologic cancer	0.000247	0.00135	CcSEcCtD
Icosapent—Rash—Hydroxyurea—hematologic cancer	0.000247	0.00135	CcSEcCtD
Icosapent—Dermatitis—Hydroxyurea—hematologic cancer	0.000246	0.00135	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Epirubicin—hematologic cancer	0.000246	0.00135	CcSEcCtD
Icosapent—Constipation—Gemcitabine—hematologic cancer	0.000245	0.00134	CcSEcCtD
Icosapent—Anaphylactic shock—Etoposide—hematologic cancer	0.000245	0.00134	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Cisplatin—hematologic cancer	0.000243	0.00133	CcSEcCtD
Icosapent—Anaphylactic shock—Prednisolone—hematologic cancer	0.000241	0.00132	CcSEcCtD
Icosapent—Pruritus—Thiotepa—hematologic cancer	0.000241	0.00132	CcSEcCtD
Icosapent—Pruritus—Thalidomide—hematologic cancer	0.000233	0.00128	CcSEcCtD
Icosapent—Aspartate aminotransferase increased—Doxorubicin—hematologic cancer	0.000232	0.00127	CcSEcCtD
Icosapent—Vomiting—Bortezomib—hematologic cancer	0.000232	0.00127	CcSEcCtD
Icosapent—Gastrointestinal disorder—Cisplatin—hematologic cancer	0.00023	0.00126	CcSEcCtD
Icosapent—Vomiting—Bleomycin—hematologic cancer	0.00023	0.00126	CcSEcCtD
Icosapent—Rash—Bortezomib—hematologic cancer	0.00023	0.00126	CcSEcCtD
Icosapent—Dermatitis—Bortezomib—hematologic cancer	0.00023	0.00126	CcSEcCtD
Icosapent—Rash—Bleomycin—hematologic cancer	0.000228	0.00125	CcSEcCtD
Icosapent—Dermatitis—Bleomycin—hematologic cancer	0.000228	0.00125	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Doxorubicin—hematologic cancer	0.000228	0.00125	CcSEcCtD
Icosapent—Vomiting—Vinorelbine—hematologic cancer	0.000227	0.00124	CcSEcCtD
Icosapent—Rash—Vinorelbine—hematologic cancer	0.000225	0.00123	CcSEcCtD
Icosapent—Dermatitis—Vinorelbine—hematologic cancer	0.000225	0.00123	CcSEcCtD
Icosapent—Anaphylactic shock—Triamcinolone—hematologic cancer	0.000222	0.00121	CcSEcCtD
Icosapent—Pruritus—Alitretinoin—hematologic cancer	0.000222	0.00121	CcSEcCtD
Icosapent—Pruritus—Ifosfamide—hematologic cancer	0.000219	0.0012	CcSEcCtD
Icosapent—Vomiting—Thiotepa—hematologic cancer	0.000216	0.00118	CcSEcCtD
Icosapent—Malnutrition—Prednisone—hematologic cancer	0.000215	0.00118	CcSEcCtD
Icosapent—Rash—Thiotepa—hematologic cancer	0.000215	0.00117	CcSEcCtD
Icosapent—Dermatitis—Thiotepa—hematologic cancer	0.000214	0.00117	CcSEcCtD
Icosapent—Gastrointestinal disorder—Etoposide—hematologic cancer	0.000211	0.00116	CcSEcCtD
Icosapent—Vomiting—Thalidomide—hematologic cancer	0.000209	0.00115	CcSEcCtD
Icosapent—Constipation—Etoposide—hematologic cancer	0.000209	0.00114	CcSEcCtD
Icosapent—Rash—Thalidomide—hematologic cancer	0.000208	0.00114	CcSEcCtD
Icosapent—Dermatitis—Thalidomide—hematologic cancer	0.000207	0.00114	CcSEcCtD
Icosapent—Pruritus—Gemcitabine—hematologic cancer	0.000203	0.00111	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	0.000202	0.00111	CcSEcCtD
Icosapent—Anaphylactic shock—Betamethasone—hematologic cancer	0.000201	0.0011	CcSEcCtD
Icosapent—Anaphylactic shock—Dexamethasone—hematologic cancer	0.000201	0.0011	CcSEcCtD
Icosapent—Vomiting—Carmustine—hematologic cancer	0.000201	0.0011	CcSEcCtD
Icosapent—Rash—Carmustine—hematologic cancer	0.000199	0.00109	CcSEcCtD
Icosapent—Dermatitis—Carmustine—hematologic cancer	0.000199	0.00109	CcSEcCtD
Icosapent—Vomiting—Alitretinoin—hematologic cancer	0.000199	0.00109	CcSEcCtD
Icosapent—Rash—Alitretinoin—hematologic cancer	0.000198	0.00108	CcSEcCtD
Icosapent—Dermatitis—Alitretinoin—hematologic cancer	0.000197	0.00108	CcSEcCtD
Icosapent—Vomiting—Ifosfamide—hematologic cancer	0.000197	0.00108	CcSEcCtD
Icosapent—Dyspepsia—Triamcinolone—hematologic cancer	0.000195	0.00107	CcSEcCtD
Icosapent—Rash—Ifosfamide—hematologic cancer	0.000195	0.00107	CcSEcCtD
Icosapent—Dermatitis—Ifosfamide—hematologic cancer	0.000195	0.00107	CcSEcCtD
Icosapent—Vomiting—Vincristine—hematologic cancer	0.000192	0.00105	CcSEcCtD
Icosapent—Rash—Vincristine—hematologic cancer	0.00019	0.00104	CcSEcCtD
Icosapent—Dermatitis—Vincristine—hematologic cancer	0.00019	0.00104	CcSEcCtD
Icosapent—Vomiting—Irinotecan—hematologic cancer	0.000187	0.00102	CcSEcCtD
Icosapent—Vomiting—Mitoxantrone—hematologic cancer	0.000187	0.00102	CcSEcCtD
Icosapent—Rash—Mitoxantrone—hematologic cancer	0.000185	0.00101	CcSEcCtD
Icosapent—Rash—Irinotecan—hematologic cancer	0.000185	0.00101	CcSEcCtD
Icosapent—Dermatitis—Mitoxantrone—hematologic cancer	0.000185	0.00101	CcSEcCtD
Icosapent—Dermatitis—Irinotecan—hematologic cancer	0.000185	0.00101	CcSEcCtD
Icosapent—PTGS2—Fluocinonide—Dexamethasone—hematologic cancer	0.000184	0.0329	CbGdCrCtD
Icosapent—PTGS2—Fluocinonide—Betamethasone—hematologic cancer	0.000184	0.0329	CbGdCrCtD
Icosapent—Musculoskeletal discomfort—Betamethasone—hematologic cancer	0.000183	0.001	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	0.000183	0.001	CcSEcCtD
Icosapent—Arthralgia—Prednisone—hematologic cancer	0.000183	0.001	CcSEcCtD
Icosapent—Vomiting—Gemcitabine—hematologic cancer	0.000182	0.000997	CcSEcCtD
Icosapent—Rash—Gemcitabine—hematologic cancer	0.000181	0.000988	CcSEcCtD
Icosapent—Dermatitis—Gemcitabine—hematologic cancer	0.00018	0.000987	CcSEcCtD
Icosapent—PTGS2—Fluocinonide—Triamcinolone—hematologic cancer	0.00018	0.0321	CbGdCrCtD
Icosapent—Malnutrition—Methotrexate—hematologic cancer	0.000179	0.000982	CcSEcCtD
Icosapent—Dyspepsia—Dexamethasone—hematologic cancer	0.000177	0.00097	CcSEcCtD
Icosapent—Dyspepsia—Betamethasone—hematologic cancer	0.000177	0.00097	CcSEcCtD
Icosapent—Dysgeusia—Methotrexate—hematologic cancer	0.000176	0.000962	CcSEcCtD
Icosapent—Anaphylactic shock—Prednisone—hematologic cancer	0.000175	0.000959	CcSEcCtD
Icosapent—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000174	0.000951	CcSEcCtD
Icosapent—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000174	0.000951	CcSEcCtD
Icosapent—Pruritus—Etoposide—hematologic cancer	0.000173	0.000947	CcSEcCtD
Icosapent—Vomiting—Cisplatin—hematologic cancer	0.00017	0.000929	CcSEcCtD
Icosapent—Rash—Cisplatin—hematologic cancer	0.000168	0.000921	CcSEcCtD
Icosapent—Dermatitis—Cisplatin—hematologic cancer	0.000168	0.00092	CcSEcCtD
Icosapent—Malnutrition—Epirubicin—hematologic cancer	0.000168	0.000919	CcSEcCtD
Icosapent—Dysgeusia—Epirubicin—hematologic cancer	0.000164	0.0009	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Prednisone—hematologic cancer	0.00016	0.000874	CcSEcCtD
Icosapent—Pruritus—Triamcinolone—hematologic cancer	0.000157	0.000859	CcSEcCtD
Icosapent—Vomiting—Etoposide—hematologic cancer	0.000155	0.000851	CcSEcCtD
Icosapent—Malnutrition—Doxorubicin—hematologic cancer	0.000155	0.000851	CcSEcCtD
Icosapent—Dyspepsia—Prednisone—hematologic cancer	0.000154	0.000845	CcSEcCtD
Icosapent—Rash—Etoposide—hematologic cancer	0.000154	0.000844	CcSEcCtD
Icosapent—Dermatitis—Etoposide—hematologic cancer	0.000154	0.000843	CcSEcCtD
Icosapent—Arthralgia—Methotrexate—hematologic cancer	0.000153	0.000836	CcSEcCtD
Icosapent—Dysgeusia—Doxorubicin—hematologic cancer	0.000152	0.000833	CcSEcCtD
Icosapent—Rash—Prednisolone—hematologic cancer	0.000152	0.000832	CcSEcCtD
Icosapent—Dermatitis—Prednisolone—hematologic cancer	0.000152	0.000832	CcSEcCtD
Icosapent—Constipation—Prednisone—hematologic cancer	0.00015	0.00082	CcSEcCtD
Icosapent—Anaphylactic shock—Methotrexate—hematologic cancer	0.000146	0.000802	CcSEcCtD
Icosapent—Arthralgia—Epirubicin—hematologic cancer	0.000143	0.000783	CcSEcCtD
Icosapent—Pruritus—Dexamethasone—hematologic cancer	0.000142	0.000779	CcSEcCtD
Icosapent—Pruritus—Betamethasone—hematologic cancer	0.000142	0.000779	CcSEcCtD
Icosapent—Vomiting—Triamcinolone—hematologic cancer	0.000141	0.000772	CcSEcCtD
Icosapent—Rash—Triamcinolone—hematologic cancer	0.00014	0.000766	CcSEcCtD
Icosapent—Dermatitis—Triamcinolone—hematologic cancer	0.00014	0.000765	CcSEcCtD
Icosapent—Anaphylactic shock—Epirubicin—hematologic cancer	0.000137	0.00075	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Methotrexate—hematologic cancer	0.000133	0.000731	CcSEcCtD
Icosapent—Arthralgia—Doxorubicin—hematologic cancer	0.000132	0.000724	CcSEcCtD
Icosapent—Dyspepsia—Methotrexate—hematologic cancer	0.000129	0.000706	CcSEcCtD
Icosapent—Vomiting—Betamethasone—hematologic cancer	0.000128	0.0007	CcSEcCtD
Icosapent—Vomiting—Dexamethasone—hematologic cancer	0.000128	0.0007	CcSEcCtD
Icosapent—Rash—Dexamethasone—hematologic cancer	0.000127	0.000695	CcSEcCtD
Icosapent—Rash—Betamethasone—hematologic cancer	0.000127	0.000695	CcSEcCtD
Icosapent—Anaphylactic shock—Doxorubicin—hematologic cancer	0.000127	0.000694	CcSEcCtD
Icosapent—Dermatitis—Dexamethasone—hematologic cancer	0.000127	0.000694	CcSEcCtD
Icosapent—Dermatitis—Betamethasone—hematologic cancer	0.000127	0.000694	CcSEcCtD
Icosapent—Gastrointestinal disorder—Methotrexate—hematologic cancer	0.000126	0.000692	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Epirubicin—hematologic cancer	0.000125	0.000684	CcSEcCtD
Icosapent—Pruritus—Prednisone—hematologic cancer	0.000124	0.000679	CcSEcCtD
Icosapent—Dyspepsia—Epirubicin—hematologic cancer	0.000121	0.000661	CcSEcCtD
Icosapent—Gastrointestinal disorder—Epirubicin—hematologic cancer	0.000118	0.000648	CcSEcCtD
Icosapent—Constipation—Epirubicin—hematologic cancer	0.000117	0.000642	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	0.000116	0.000633	CcSEcCtD
Icosapent—Dyspepsia—Doxorubicin—hematologic cancer	0.000112	0.000611	CcSEcCtD
Icosapent—Vomiting—Prednisone—hematologic cancer	0.000111	0.00061	CcSEcCtD
Icosapent—PTGS2—Fluticasone Propionate—Betamethasone—hematologic cancer	0.000111	0.0198	CbGdCrCtD
Icosapent—PTGS2—Fluticasone Propionate—Dexamethasone—hematologic cancer	0.000111	0.0198	CbGdCrCtD
Icosapent—Rash—Prednisone—hematologic cancer	0.000111	0.000605	CcSEcCtD
Icosapent—Dermatitis—Prednisone—hematologic cancer	0.00011	0.000604	CcSEcCtD
Icosapent—Gastrointestinal disorder—Doxorubicin—hematologic cancer	0.00011	0.000599	CcSEcCtD
Icosapent—Constipation—Doxorubicin—hematologic cancer	0.000108	0.000594	CcSEcCtD
Icosapent—PTGS2—Fluticasone Propionate—Triamcinolone—hematologic cancer	0.000108	0.0194	CbGdCrCtD
Icosapent—Pruritus—Methotrexate—hematologic cancer	0.000104	0.000567	CcSEcCtD
Icosapent—Pruritus—Epirubicin—hematologic cancer	9.7e-05	0.000531	CcSEcCtD
Icosapent—Vomiting—Methotrexate—hematologic cancer	9.31e-05	0.00051	CcSEcCtD
Icosapent—Rash—Methotrexate—hematologic cancer	9.24e-05	0.000506	CcSEcCtD
Icosapent—Dermatitis—Methotrexate—hematologic cancer	9.23e-05	0.000505	CcSEcCtD
Icosapent—Pruritus—Doxorubicin—hematologic cancer	8.97e-05	0.000491	CcSEcCtD
Icosapent—Vomiting—Epirubicin—hematologic cancer	8.72e-05	0.000477	CcSEcCtD
Icosapent—Rash—Epirubicin—hematologic cancer	8.64e-05	0.000473	CcSEcCtD
Icosapent—Dermatitis—Epirubicin—hematologic cancer	8.64e-05	0.000473	CcSEcCtD
Icosapent—Vomiting—Doxorubicin—hematologic cancer	8.07e-05	0.000441	CcSEcCtD
Icosapent—Rash—Doxorubicin—hematologic cancer	8e-05	0.000438	CcSEcCtD
Icosapent—Dermatitis—Doxorubicin—hematologic cancer	7.99e-05	0.000437	CcSEcCtD
Icosapent—FFAR1—Signaling Pathways—EP300—hematologic cancer	1.23e-05	5.77e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—ALOX5—hematologic cancer	1.21e-05	5.7e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—CREBBP—hematologic cancer	1.21e-05	5.69e-05	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—hematologic cancer	1.21e-05	5.67e-05	CbGpPWpGaD
Icosapent—FADS1—Metabolism—PIK3CA—hematologic cancer	1.2e-05	5.64e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.2e-05	5.64e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—ARNTL—hematologic cancer	1.2e-05	5.62e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—SRC—hematologic cancer	1.19e-05	5.61e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—NPM1—hematologic cancer	1.19e-05	5.6e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—CYCS—hematologic cancer	1.19e-05	5.57e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—HSP90AA1—hematologic cancer	1.18e-05	5.54e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—NUP98—hematologic cancer	1.18e-05	5.53e-05	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—hematologic cancer	1.17e-05	5.51e-05	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—hematologic cancer	1.17e-05	5.5e-05	CbGpPWpGaD
Icosapent—ACSL3—Metabolism—AKT1—hematologic cancer	1.17e-05	5.5e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CA9—hematologic cancer	1.16e-05	5.47e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—ACP5—hematologic cancer	1.16e-05	5.47e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—VEGFA—hematologic cancer	1.16e-05	5.46e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—STAT3—hematologic cancer	1.15e-05	5.41e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—PIK3CD—hematologic cancer	1.15e-05	5.4e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—NCOR2—hematologic cancer	1.15e-05	5.39e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—NRAS—hematologic cancer	1.15e-05	5.39e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—NR3C1—hematologic cancer	1.14e-05	5.37e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—ADCY7—hematologic cancer	1.14e-05	5.36e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—NCOA3—hematologic cancer	1.14e-05	5.36e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—FGF19—hematologic cancer	1.14e-05	5.36e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—NUP214—hematologic cancer	1.13e-05	5.33e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—ALB—hematologic cancer	1.13e-05	5.33e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—RPS14—hematologic cancer	1.13e-05	5.32e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—EP300—hematologic cancer	1.13e-05	5.32e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—DKK1—hematologic cancer	1.12e-05	5.28e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.12e-05	5.27e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—STAT5B—hematologic cancer	1.12e-05	5.24e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—NUP98—hematologic cancer	1.12e-05	5.24e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—MTR—hematologic cancer	1.11e-05	5.22e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—ABCG2—hematologic cancer	1.11e-05	5.22e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—SRC—hematologic cancer	1.1e-05	5.17e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—MAPK3—hematologic cancer	1.1e-05	5.17e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—IDH1—hematologic cancer	1.09e-05	5.14e-05	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	1.09e-05	5.14e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CST3—hematologic cancer	1.09e-05	5.12e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—ENO2—hematologic cancer	1.09e-05	5.12e-05	CbGpPWpGaD
Icosapent—FFAR1—Metabolism—PIK3CA—hematologic cancer	1.09e-05	5.1e-05	CbGpPWpGaD
Icosapent—ACSL4—Metabolism—PIK3CA—hematologic cancer	1.09e-05	5.1e-05	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	1.08e-05	5.09e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—PIK3R1—hematologic cancer	1.08e-05	5.09e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—ADCY7—hematologic cancer	1.08e-05	5.08e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—ABCC3—hematologic cancer	1.08e-05	5.08e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—GSTO1—hematologic cancer	1.08e-05	5.08e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—TXN—hematologic cancer	1.08e-05	5.08e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—NUP214—hematologic cancer	1.07e-05	5.05e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—VEGFA—hematologic cancer	1.07e-05	5.04e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—MYC—hematologic cancer	1.07e-05	5.02e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—TGFB1—hematologic cancer	1.07e-05	5.01e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—STAT3—hematologic cancer	1.06e-05	4.99e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.06e-05	4.98e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—NRAS—hematologic cancer	1.06e-05	4.98e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—SPHK1—hematologic cancer	1.06e-05	4.97e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—GSTT1—hematologic cancer	1.06e-05	4.96e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—XIAP—hematologic cancer	1.05e-05	4.95e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—MTR—hematologic cancer	1.05e-05	4.95e-05	CbGpPWpGaD
Icosapent—PPARG—Generic Transcription Pathway—MYC—hematologic cancer	1.05e-05	4.93e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—GSTP1—hematologic cancer	1.05e-05	4.91e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.04e-05	4.89e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—SDC1—hematologic cancer	1.03e-05	4.85e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—ENO2—hematologic cancer	1.03e-05	4.85e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—SMARCA4—hematologic cancer	1.03e-05	4.82e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—UGT1A1—hematologic cancer	1.02e-05	4.78e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—MAPK3—hematologic cancer	1.01e-05	4.77e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.01e-05	4.75e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—PIK3CB—hematologic cancer	1e-05	4.7e-05	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	9.96e-06	4.68e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—ABCB1—hematologic cancer	9.9e-06	4.65e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—SLC22A1—hematologic cancer	9.89e-06	4.65e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CRABP1—hematologic cancer	9.89e-06	4.65e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—MAPK14—hematologic cancer	9.89e-06	4.65e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—KRAS—hematologic cancer	9.88e-06	4.64e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	9.86e-06	4.63e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—TGFB1—hematologic cancer	9.85e-06	4.62e-05	CbGpPWpGaD
Icosapent—FADS1—Metabolism—AKT1—hematologic cancer	9.81e-06	4.61e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—SDC1—hematologic cancer	9.79e-06	4.6e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	9.74e-06	4.57e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—ESR1—hematologic cancer	9.71e-06	4.56e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—ALOX5—hematologic cancer	9.64e-06	4.53e-05	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	9.64e-06	4.53e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—GSTM1—hematologic cancer	9.61e-06	4.51e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—NCOR1—hematologic cancer	9.61e-06	4.51e-05	CbGpPWpGaD
Icosapent—PPARD—Gene Expression—MAPK3—hematologic cancer	9.51e-06	4.47e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—LCK—hematologic cancer	9.48e-06	4.45e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—NOTCH1—hematologic cancer	9.38e-06	4.41e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—NUP98—hematologic cancer	9.34e-06	4.39e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	9.32e-06	4.38e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—H3F3A—hematologic cancer	9.29e-06	4.37e-05	CbGpPWpGaD
Icosapent—PPARD—Gene Expression—MYC—hematologic cancer	9.25e-06	4.34e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—TNF—hematologic cancer	9.19e-06	4.32e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—KRAS—hematologic cancer	9.12e-06	4.28e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—PIK3CA—hematologic cancer	9.08e-06	4.26e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—NCOA3—hematologic cancer	9.07e-06	4.26e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—ADCY7—hematologic cancer	9.07e-06	4.26e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PRKCZ—hematologic cancer	9.03e-06	4.24e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—NUP214—hematologic cancer	9e-06	4.23e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	8.91e-06	4.18e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CALR—hematologic cancer	8.88e-06	4.17e-05	CbGpPWpGaD
Icosapent—ACSL4—Metabolism—AKT1—hematologic cancer	8.87e-06	4.17e-05	CbGpPWpGaD
Icosapent—FFAR1—Metabolism—AKT1—hematologic cancer	8.87e-06	4.17e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—ABCG2—hematologic cancer	8.82e-06	4.14e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—MTR—hematologic cancer	8.82e-06	4.14e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—TP53—hematologic cancer	8.78e-06	4.13e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—NQO1—hematologic cancer	8.78e-06	4.12e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CD44—hematologic cancer	8.78e-06	4.12e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PARP1—hematologic cancer	8.73e-06	4.1e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—PTEN—hematologic cancer	8.65e-06	4.06e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—ENO2—hematologic cancer	8.65e-06	4.06e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	8.6e-06	4.04e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—FBXW7—hematologic cancer	8.58e-06	4.03e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—CREBBP—hematologic cancer	8.51e-06	4e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—MTHFR—hematologic cancer	8.49e-06	3.99e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—HDAC2—hematologic cancer	8.42e-06	3.95e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CXCR4—hematologic cancer	8.42e-06	3.95e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—HRAS—hematologic cancer	8.4e-06	3.95e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—GSTT1—hematologic cancer	8.39e-06	3.94e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CD44—hematologic cancer	8.32e-06	3.91e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CYCS—hematologic cancer	8.31e-06	3.9e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	8.26e-06	3.88e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—HSP90AA1—hematologic cancer	8.26e-06	3.88e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—EP300—hematologic cancer	8.25e-06	3.88e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CBL—hematologic cancer	8.2e-06	3.85e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—SDC1—hematologic cancer	8.2e-06	3.85e-05	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	8.14e-06	3.82e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—IL6—hematologic cancer	8.04e-06	3.78e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	7.83e-06	3.68e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—HSP90AA1—hematologic cancer	7.83e-06	3.68e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—HRAS—hematologic cancer	7.75e-06	3.64e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	7.73e-06	3.63e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—STAT1—hematologic cancer	7.55e-06	3.54e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	7.48e-06	3.51e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	7.43e-06	3.49e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—IL6—hematologic cancer	7.42e-06	3.48e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—AKT1—hematologic cancer	7.42e-06	3.48e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	7.39e-06	3.47e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—GSTP1—hematologic cancer	7.32e-06	3.44e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—PIK3CG—hematologic cancer	7.13e-06	3.35e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	7.09e-06	3.33e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—GRB2—hematologic cancer	7.06e-06	3.32e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PDGFA—hematologic cancer	7.04e-06	3.31e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CD44—hematologic cancer	6.97e-06	3.27e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—NQO1—hematologic cancer	6.97e-06	3.27e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—KITLG—hematologic cancer	6.94e-06	3.26e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—ABCB1—hematologic cancer	6.93e-06	3.26e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—AKT1—hematologic cancer	6.84e-06	3.21e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	6.83e-06	3.21e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—STAT5A—hematologic cancer	6.79e-06	3.19e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—GSTM1—hematologic cancer	6.73e-06	3.16e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—NCOR1—hematologic cancer	6.73e-06	3.16e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CDKN2B—hematologic cancer	6.73e-06	3.16e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—CREBBP—hematologic cancer	6.61e-06	3.11e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CYCS—hematologic cancer	6.6e-06	3.1e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—HSP90AA1—hematologic cancer	6.55e-06	3.08e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CD86—hematologic cancer	6.51e-06	3.06e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—HES1—hematologic cancer	6.42e-06	3.01e-05	CbGpPWpGaD
Icosapent—PPARD—Gene Expression—AKT1—hematologic cancer	6.41e-06	3.01e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—NCOR1—hematologic cancer	6.38e-06	3e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—FGF1—hematologic cancer	6.31e-06	2.96e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—PIK3CD—hematologic cancer	6.27e-06	2.95e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—FOXO1—hematologic cancer	6.22e-06	2.92e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PDGFRB—hematologic cancer	6.21e-06	2.92e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—ALB—hematologic cancer	6.19e-06	2.91e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PDGFRA—hematologic cancer	6.11e-06	2.87e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—PIK3CA—hematologic cancer	6.1e-06	2.87e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—JAK1—hematologic cancer	6.09e-06	2.86e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PRKCG—hematologic cancer	6.09e-06	2.86e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—MTHFR—hematologic cancer	5.95e-06	2.79e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—PIK3R1—hematologic cancer	5.92e-06	2.78e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.9e-06	2.77e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—GSTP1—hematologic cancer	5.81e-06	2.73e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—MTHFR—hematologic cancer	5.64e-06	2.65e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.63e-06	2.64e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—TERT—hematologic cancer	5.62e-06	2.64e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—HLA-A—hematologic cancer	5.62e-06	2.64e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—ABCB1—hematologic cancer	5.5e-06	2.59e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PDGFB—hematologic cancer	5.49e-06	2.58e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—PIK3CB—hematologic cancer	5.47e-06	2.57e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—TSC2—hematologic cancer	5.36e-06	2.52e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—NCOR1—hematologic cancer	5.34e-06	2.51e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—GSTM1—hematologic cancer	5.34e-06	2.51e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.24e-06	2.46e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—MAPK3—hematologic cancer	5.19e-06	2.44e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—FGFR3—hematologic cancer	5.16e-06	2.42e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—MYC—hematologic cancer	5.05e-06	2.37e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PIK3CG—hematologic cancer	5e-06	2.35e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—AKT1—hematologic cancer	4.99e-06	2.34e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—BAD—hematologic cancer	4.89e-06	2.3e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—NOTCH1—hematologic cancer	4.84e-06	2.28e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CD80—hematologic cancer	4.75e-06	2.23e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—KIT—hematologic cancer	4.74e-06	2.23e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—PTEN—hematologic cancer	4.72e-06	2.22e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—MTHFR—hematologic cancer	4.72e-06	2.22e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PTPN11—hematologic cancer	4.65e-06	2.19e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CREBBP—hematologic cancer	4.63e-06	2.18e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CREB1—hematologic cancer	4.51e-06	2.12e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—EP300—hematologic cancer	4.5e-06	2.12e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—BRAF—hematologic cancer	4.45e-06	2.09e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—IL6R—hematologic cancer	4.4e-06	2.07e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PIK3CD—hematologic cancer	4.39e-06	2.06e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CREBBP—hematologic cancer	4.39e-06	2.06e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—ALB—hematologic cancer	4.34e-06	2.04e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—MAP2K1—hematologic cancer	4.19e-06	1.97e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PIK3CD—hematologic cancer	4.16e-06	1.96e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.16e-06	1.95e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PIK3R1—hematologic cancer	4.15e-06	1.95e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—FGF2—hematologic cancer	3.99e-06	1.87e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PIK3CG—hematologic cancer	3.97e-06	1.86e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PIK3R1—hematologic cancer	3.93e-06	1.85e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PIK3CB—hematologic cancer	3.83e-06	1.8e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—JAK2—hematologic cancer	3.82e-06	1.8e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—MDM2—hematologic cancer	3.73e-06	1.75e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CREBBP—hematologic cancer	3.68e-06	1.73e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—MTOR—hematologic cancer	3.63e-06	1.7e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PIK3CB—hematologic cancer	3.63e-06	1.7e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CD4—hematologic cancer	3.62e-06	1.7e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—AKT1—hematologic cancer	3.5e-06	1.64e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PIK3CD—hematologic cancer	3.49e-06	1.64e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—ALB—hematologic cancer	3.44e-06	1.62e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CDKN1B—hematologic cancer	3.41e-06	1.6e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—PIK3CA—hematologic cancer	3.33e-06	1.57e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PTEN—hematologic cancer	3.31e-06	1.55e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PIK3R1—hematologic cancer	3.29e-06	1.55e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—EP300—hematologic cancer	3.16e-06	1.48e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CDKN1A—hematologic cancer	3.14e-06	1.48e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PTEN—hematologic cancer	3.14e-06	1.47e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PIK3CB—hematologic cancer	3.04e-06	1.43e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—EP300—hematologic cancer	2.99e-06	1.41e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—SRC—hematologic cancer	2.91e-06	1.37e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—STAT3—hematologic cancer	2.81e-06	1.32e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—NRAS—hematologic cancer	2.8e-06	1.31e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—AKT1—hematologic cancer	2.72e-06	1.28e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—MAPK3—hematologic cancer	2.68e-06	1.26e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PTEN—hematologic cancer	2.63e-06	1.23e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—MYC—hematologic cancer	2.61e-06	1.22e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—TGFB1—hematologic cancer	2.6e-06	1.22e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—EP300—hematologic cancer	2.51e-06	1.18e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—KRAS—hematologic cancer	2.41e-06	1.13e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PIK3CA—hematologic cancer	2.33e-06	1.1e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PIK3CA—hematologic cancer	2.21e-06	1.04e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—HRAS—hematologic cancer	2.05e-06	9.62e-06	CbGpPWpGaD
Icosapent—PTGS2—Disease—IL6—hematologic cancer	1.96e-06	9.2e-06	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—AKT1—hematologic cancer	1.91e-06	8.96e-06	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PIK3CA—hematologic cancer	1.85e-06	8.7e-06	CbGpPWpGaD
Icosapent—PTGS2—Disease—AKT1—hematologic cancer	1.81e-06	8.49e-06	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—AKT1—hematologic cancer	1.51e-06	7.11e-06	CbGpPWpGaD
